Our ex vivo and in vivo results with NUP98-r AML models suggest that samples expressing mutated WT1 or FLT3-ITD respond favorably to MLL–Menin inhibition, indicating that these mutations do not necessarily lead to treatment resistance. This evidence concerns the gene FLT3 and acute myeloid leukemia.